REGN241115P1012500
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Wolfe Research Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,150
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Regeneron Pharma Initiated at Neutral by Citigroup
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895
Express News | Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at Ash
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
Regeneron Announces Investor Conference Presentations
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,175
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
Regeneron Pharma Is Maintained at Outperform by Oppenheimer
Regeneron Pharmaceuticals Analyst Ratings
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,000
Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment
Express News | Regeneron - Dupixent (Dupilumab) Approved in European Union as First and Only Medicine for Young Children With Eosinophilic Esophagitis
Dupixent (Dupilumab) Approved in the European Union as the First and Only Medicine for Young Children With Eosinophilic Esophagitis
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,126